Biologics to Treat Acute Asthma and COPD Exacerbations: A Rapid Review

Background/Objectives: Biologics targeting type-2 inflammation represent maintenance medications that reduce asthma and chronic obstructive pulmonary disease (COPD) exacerbation risk. Whether biologics may be used to treat acute exacerbations, specifically administered during the exacerbation itself, is an emerging paradigm. The purpose of this review was to identify and characterize biologics treating acute asthma or COPD. Methods: This was a rapid, systematic review of biologics to treat acute exacerbations of asthma or COPD. Databases searched included Ovid MEDLINE, Ovid Embase, and Scopus. Experimental and observational studies were eligible. Records were independently screened and appraised by four investigators and extracted by one investigator. Quality appraisal was conducted using RoB 2 and JBI instruments for experimental studies and case reports, respectively. Results: Two randomized controlled studies and 30 case reports/series (37 patients) were eligible for inclusion. Benralizumab and omalizumab were the most reported biologics (n = 10 and n = 9 studies, respectively). The ABRA trial noted benralizumab reduced 90-day treatment failure, though the COPD-HELP trial evaluating mepolizumab did not observe mortality or readmission reductions. Case report-level data often described near-fatal or life-threatening asthma exacerbations treated in intensive care units; all patients with reported survival outcomes (n = 36) survived. Conclusions: Emerging evidence suggests biologics administered during exacerbations may improve acute care outcomes, predominantly in asthma; evidence in COPD is limited. The current evidence should be viewed as exploratory; further randomized trials evaluating biologic administration, particularly in COPD, are warranted.

Authors

Institutions

Publication Details

Journal
Biologics
Published
2026-11-16
DOI
https://doi.org/10.3390/biologics6040036
Primary Topic
Asthma and respiratory diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Biologics to Treat Acute Asthma and COPD Exacerbations: A Rapid Review

Alyssa N. Campbell, Paul M. Boylan, Rachel K. Vu, Bryson S. Duncan
1 links
Biologics
Asthma and respiratory diseases
article

Biologics to Treat Acute Asthma and COPD Exacerbations: A Rapid Review

Alyssa N. Campbell, Paul M. Boylan, Rachel K. Vu, Bryson S. Duncan
article en

Abstract

Background/Objectives: Biologics targeting type-2 inflammation represent maintenance medications that reduce asthma and chronic obstructive pulmonary disease (COPD) exacerbation risk. Whether biologics may be used to treat acute exacerbations, specifically administered during the exacerbation itself, is an emerging paradigm. The purpose of this review was to identify and characterize biologics treating acute asthma or COPD. Methods: This was a rapid, systematic review of biologics to treat acute exacerbations of asthma or COPD. Databases searched included Ovid MEDLINE, Ovid Embase, and Scopus. Experimental and observational studies were eligible. Records were independently screened and appraised by four investigators and extracted by one investigator. Quality appraisal was conducted using RoB 2 and JBI instruments for experimental studies and case reports, respectively. Results: Two randomized controlled studies and 30 case reports/series (37 patients) were eligible for inclusion. Benralizumab and omalizumab were the most reported biologics (n = 10 and n = 9 studies, respectively). The ABRA trial noted benralizumab reduced 90-day treatment failure, though the COPD-HELP trial evaluating mepolizumab did not observe mortality or readmission reductions. Case report-level data often described near-fatal or life-threatening asthma exacerbations treated in intensive care units; all patients with reported survival outcomes (n = 36) survived. Conclusions: Emerging evidence suggests biologics administered during exacerbations may improve acute care outcomes, predominantly in asthma; evidence in COPD is limited. The current evidence should be viewed as exploratory; further randomized trials evaluating biologic administration, particularly in COPD, are warranted.

BiologicsVol. 6(4)
University of Oklahoma Health Sciences Center (US), University of Oklahoma (US)
Good health and well-being
Asthma and respiratory diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon